Skip to main content
Clinical Trials/NCT00639106
NCT00639106CompletedPhase 3

The Use of Alloderm in Two-Stage, Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial

Memorial Sloan Kettering Cancer Center3 sites in 1 country70 target enrollmentStarted: March 1, 2008Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
70
Locations
3
Primary Endpoint
whether using Alloderm to create the inferior-medial portion of the expander pocket will decrease patient-reported pain in both the immediate, post-operative period and during the expansion phase.

Study Overview

Brief Summary

Following mastectomy (removal of your breast), reconstruction of your breast(s) can be performed using tissue expanders and implants. At the same operation as your mastectomy, a tissue expander is put under the skin and muscles of your chest.

Following your surgery, the tissue expander is gradually filled with salt water over a period of months. Once the expander is filled to the size of your new breast, a second operation is performed. At this time, the tissue expander is removed and a permanent breast implant is placed. This is a standard procedure. We are interested in learning about the use of AlloDerm in breast reconstruction. AlloDerm can be used instead of some of your own chest muscles, in order to cover and protect a tissue expander. We want to know if the use of AlloDerm can decrease your pain or discomfort after surgery and after the filling of your tissue expander.

AlloDerm is made from human tissue. When AlloDerm is made all the cells that could cause your body to reject it are removed. When it is placed in your chest, your own cells will then grow into the AlloDerm, causing it to act like the muscle it is replacing. In this study, you will either have reconstruction with AlloDerm or without AlloDerm.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
21 Years to 75 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients who undergo immediate, postmastectomy, tissue expander/implant reconstruction
  • •Patients ≥ 21 and ≤ 75 years of age

Exclusion Criteria

  • •Patient refusal
  • •Patients who will undergo any of the following:
  • •Single-stage implant reconstruction
  • •Combined autogenous tissue expander/implant reconstruction
  • •Patients with a history of prior irradiation
  • •Patients with a history of prior surgery with breast implants
  • •Patients with a history of prior axillary lymph node dissection
  • •Patients who are pregnant
  • •The following eligibility will be confirmed at the time of surgery.
  • •Patients who are deemed intraoperatively by the attending surgeon to have significant mastectomy flap ischemia.
  • •Patients who have an axillary lymph node dissection at the time of mastectomy (Patients undergoing sentinel lymph biopsy are eligible)

Arms & Interventions

A

Experimental

Expander Placement WITH Alloderm

Intervention: Alloderm, Questionnaires (Procedure)

B

Active Comparator

Expander Placement WITHOUT Alloderm

Intervention: Without ALLODERM, Questionnaires (Procedure)

Outcomes

Primary Outcomes

whether using Alloderm to create the inferior-medial portion of the expander pocket will decrease patient-reported pain in both the immediate, post-operative period and during the expansion phase.

Time Frame: conclusion of the study

Secondary Outcomes

  • To evaluate whether the use of Alloderm in tissue expander/implant reconstruction affects the rate of postoperative expansion and in-hospital narcotic use.(conclusion of the study)
  • To examine if the use of Alloderm will impact both chronic breast pain and sensory morbidity.(conclusion of the study)
  • To examine the effect of Alloderm on the overall aesthetic outcome, including the formation of capsular contracture, following tissue expander/implant reconstruction.(conclusion of the study)
  • To examine if the use of Alloderm will decrease patient-reported sensory morbidity in both the immediate, post-operative period and during the expansion phase.(conclusion of the study)
  • To evaluate patient satisfaction following postmastectomy, tissue expander-implant reconstruction with and without the use of Alloderm.(conclusion of the study)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials